The Unlikely Duo: Qantas and ResMed – A Tale of Trust, Technology, and Market Valuation
There’s something intriguing about comparing companies that, on the surface, couldn’t be more different. Qantas Airways (ASX:QAN), Australia’s aviation giant, and ResMed (ASX:RMD), a global leader in sleep apnea technology, might seem like an odd pair. Yet, their recent market trajectories and public perceptions offer a fascinating lens into how industries evolve, and how investors perceive value. Personally, I think this juxtaposition highlights a broader truth: success isn’t just about what you sell, but how you’re perceived and how you adapt.
Qantas: The Trust Deficit and the Revenue Paradox
Qantas, founded in 1921, is a household name in Australia. With its dominance in domestic and international flights, freight services, and the iconic Frequent Flyer program, it’s hard to imagine Australian travel without it. Yet, here’s the irony: despite its market power, Qantas has become one of the country’s most distrusted brands. What makes this particularly fascinating is that, even as consumer trust wanes, the airline’s revenue and profits have grown post-pandemic.
From my perspective, this disconnect speaks to a larger trend in modern business. Market dominance can sometimes breed complacency, and Qantas’s struggles with public perception are a cautionary tale. What many people don’t realize is that trust is a currency—one that Qantas seems to be spending faster than it’s earning. If you take a step back and think about it, this raises a deeper question: Can a company sustain growth without public goodwill? I’m not so sure.
The valuation of QAN shares adds another layer of intrigue. With a price-sales ratio of 0.69x, below its 5-year average of 0.88x, the stock appears undervalued. But is this an opportunity or a warning sign? In my opinion, the market is pricing in the risks of a trust deficit, even as revenue climbs. It’s a reminder that financial metrics are just one piece of the puzzle.
ResMed: The Quiet Innovator in a Noisy Sector
Now, let’s pivot to ResMed. Founded in Australia but now headquartered in San Diego, this company operates in a completely different sphere—medical technology. Its cloud-connected CPAP machines and SaaS solutions for sleep apnea and respiratory care are nothing short of revolutionary. What makes ResMed stand out is its ability to blend hardware innovation with data-driven insights, creating a network that improves patient outcomes while reducing healthcare costs.
One thing that immediately stands out is how ResMed has managed to stay under the radar compared to flashier tech companies. Yet, its impact on global healthcare is undeniable. With operations in 140 countries and a focus on out-of-hospital care, ResMed is quietly reshaping how we approach chronic conditions. What this really suggests is that innovation doesn’t always need a spotlight—sometimes, it thrives in the shadows.
The valuation of RMD shares is equally compelling. Trading at a price-sales ratio of 4.11x, well below its 5-year average of 8.70x, the stock seems undervalued. But here’s where it gets interesting: unlike Qantas, ResMed’s lower valuation might reflect market skepticism about its growth potential, not a trust deficit. In my opinion, this could be a mispricing—a hidden gem in a sector ripe for disruption.
The Broader Implications: Trust, Technology, and Market Mispricing
If there’s one thing these two companies teach us, it’s that valuation metrics are just the tip of the iceberg. Qantas’s trust issues and ResMed’s quiet innovation highlight the intangible factors that drive investor sentiment. What many people don’t realize is that markets often misprice companies based on short-term narratives, overlooking long-term potential.
For Qantas, the question is whether it can rebuild trust while maintaining its market dominance. For ResMed, the challenge is whether it can sustain its innovation edge in a competitive healthcare landscape. Both companies are at a crossroads, and their trajectories will likely diverge based on how they navigate these challenges.
Final Thoughts: The Art of Seeing Beyond the Numbers
As I reflect on Qantas and ResMed, I’m reminded that investing isn’t just about crunching numbers—it’s about understanding the stories behind them. Qantas’s trust deficit and ResMed’s quiet innovation are more than just corporate narratives; they’re lessons in how perception, technology, and adaptability shape value.
Personally, I’m keeping a close eye on both stocks in 2026. Qantas, because it’s a test case for whether market power can survive a trust crisis. ResMed, because it’s a reminder that true innovation often flies under the radar. If you take a step back and think about it, these companies aren’t just stocks—they’re case studies in the complexities of modern business. And that, in my opinion, is what makes them worth watching.
